You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for New Drug Application (NDA): 203634


✉ Email this page to a colleague

« Back to Dashboard


NDA 203634 describes UCERIS, which is a drug marketed by Salix and is included in two NDAs. It is available from four suppliers. There are five patents protecting this drug and one Paragraph IV challenge. Additional details are available on the UCERIS profile page.

The generic ingredient in UCERIS is budesonide. There are twenty-two drug master file entries for this compound. Forty-three suppliers are listed for this compound. Additional details are available on the budesonide profile page.
Summary for 203634
Tradename:UCERIS
Applicant:Salix
Ingredient:budesonide
Patents:5
Pharmacology for NDA: 203634
Medical Subject Heading (MeSH) Categories for 203634
Suppliers and Packaging for NDA: 203634
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
UCERIS budesonide TABLET, EXTENDED RELEASE;ORAL 203634 NDA AUTHORIZED GENERIC Bryant Ranch Prepack 63629-9093 63629-9093-1 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (63629-9093-1)
UCERIS budesonide TABLET, EXTENDED RELEASE;ORAL 203634 NDA Santarus Inc. 68012-309 68012-309-01 2 TABLET, EXTENDED RELEASE in 1 BLISTER PACK (68012-309-01)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength9MG
Approval Date:Jan 14, 2013TE:ABRLD:Yes
Patent:⤷  SubscribePatent Expiration:Sep 7, 2031Product Flag?YSubstance Flag?Delist Request?
Patent:⤷  SubscribePatent Expiration:Sep 7, 2031Product Flag?YSubstance Flag?Delist Request?
Patent:⤷  SubscribePatent Expiration:Sep 7, 2031Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 203634

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Salix UCERIS budesonide TABLET, EXTENDED RELEASE;ORAL 203634-001 Jan 14, 2013 ⤷  Subscribe ⤷  Subscribe
Salix UCERIS budesonide TABLET, EXTENDED RELEASE;ORAL 203634-001 Jan 14, 2013 ⤷  Subscribe ⤷  Subscribe
Salix UCERIS budesonide TABLET, EXTENDED RELEASE;ORAL 203634-001 Jan 14, 2013 ⤷  Subscribe ⤷  Subscribe
Salix UCERIS budesonide TABLET, EXTENDED RELEASE;ORAL 203634-001 Jan 14, 2013 ⤷  Subscribe ⤷  Subscribe
Salix UCERIS budesonide TABLET, EXTENDED RELEASE;ORAL 203634-001 Jan 14, 2013 ⤷  Subscribe ⤷  Subscribe
Salix UCERIS budesonide TABLET, EXTENDED RELEASE;ORAL 203634-001 Jan 14, 2013 ⤷  Subscribe ⤷  Subscribe
Salix UCERIS budesonide TABLET, EXTENDED RELEASE;ORAL 203634-001 Jan 14, 2013 ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.